SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : HEB, Hemispherx Biopharma (AMEX)NEW
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Anthony@Pacific who wrote (568)11/5/1998 2:15:00 PM
From: Anthony@Pacific   of 857
 
To all HEB shareholders and Dr Carter, you are absolutely insane, you actually are trying to defend a market value in this Loser of a Company by attacking the short sellers..why don't you adress the orphan drug status that would be revoked in the evnt a market develops and explain how HEB could possibly profit from a Drug that has been written off by every Real Company, Furthermore explain why these phase three trials have taken 6 years and no new info..The FDA could and would never approve such a scam to be perpetuated upon the public,,Ampligen is useless and not one independant report claims otherwise.This is all part of Dr Carters campaign to have the average shareholder carry out his war against Scientific and financial critics ..there is no reasonto believe Phase III trials will ever conclude because it would kill the stock promotion...Dr Carter..please explain when the Phase III trials will be finished, if ever, and when we can expect an FDA review of the Data..once and for all.( It's gone on long enough)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News